Clinical Trials Browser

OTHER × Carcinoma, Neuroendocrine × pembrolizumab × Clear all

NCT03290079 2025-12-22

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Phase 2 Completed

20 enrolled 12 charts

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03012620 2024-02-28

AcSé

Phase 2 Completed

334 enrolled

CNSEndocrineGynecologicHead & NeckLymphoidSarcoma

Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Lymphoma, Extranodal NK-T-Cell

NCT03901378 2021-01-25

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

Phase 2 Withdrawn

Endocrine

Carcinoma, Neuroendocrine